US 12,240,899 B2
LAIR-1-binding agents and methods of use thereof
Suzanne Christine Crawley, Brisbane, CA (US); Bin Fan, South San Francisco, CA (US); Betty Chan Li, Millbrae, CA (US); Lee Benjamin Rivera, South San Francisco, CA (US); James Robert Sissons, South San Francisco, CA (US); Jonathan Sitrin, South San Francisco, CA (US); Yan Wang, Foster City, CA (US); and Xuan Zhao, South San Francisco, CA (US)
Assigned to NGM Biopharmaceuticals, Inc., South San Francisco, CA (US)
Filed by NGM Biopharmaceuticals, Inc., South San Francisco, CA (US)
Filed on Jun. 21, 2021, as Appl. No. 17/353,295.
Claims priority of provisional application 63/122,877, filed on Dec. 8, 2020.
Claims priority of provisional application 63/042,299, filed on Jun. 22, 2020.
Prior Publication US 2022/0041711 A1, Feb. 10, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/28 (2013.01) [A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 41 Claims
OG exemplary drawing
 
1. A binding agent that specifically binds the extracellular domain of human leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1), wherein the binding agent comprises:
(a) a heavy chain variable region (VH) comprising a VH-complementarity determining region (CDR) 1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 117; and a light chain variable region (VL) comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 118;
(b) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 119; and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 120;
(c) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 115; and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 116;
(d) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 121; and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 122;
(e) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 123; and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 124;
(f) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 125; and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 126;
(g) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 127; and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 128; or
(h) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 129; and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 130.